67.3% of Trials Disrupted by COVID-19 are Due to Enrollment Suspension

GlobalData has found that the majority of disrupted clinical trials 67.3%, were due to the suspension of enrollment. The delayed initiation of planned trials follows at 18.4%, then, 14.4% of trials are currently being impacted due to slow enrollment. 

For more information and findings, click here.